ORIGIN trial data suggest atacicept (Trutakna; Vera Therapeutics) is well tolerated in IgA nephropathy, with follow-up needed to assess long-term kidney outcomes.
Richard Lafayette, MD, FACP
Advertisement
Richard Lafayette, MD, FACP, is professor of medicine, nephrology, and director, Glomerular Disease Center, Stanford University Medical Center, and Vanrafia ALIGN study investigator and steering committee member.
Articles by Richard Lafayette, MD, FACP
The FDA approval of atacicept introduces the first BAFF/APRIL dual inhibitor for IgA nephropathy, with trial data showing significant proteinuria reduction.
Richard Lafayette, MD, FACP, explains why a REMS program is not required for the endothelin A receptor antagonist and how patients may need to adjust should final ALIGN trial data fail to show a clinical benefit of atrasentan.
Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month for proteinuria reduction.
Advertisement
Latest Updated Articles
Advertisement
Advertisement